Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    CT1812

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Cognition Therapeutics CEO Issues Letter To Shareholders
    Cognition Therapeutics CEO Issues Letter To Shareholders

    31 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/31/3266078/0/en/Cognition-Therapeutics-CEO-Issues-Letter-to-Shareholders.html

    GLOBENEWSWIRE
    31 Mar 2026
    Share Share
    Cognition Therapeutics Reports 2025 Results, Clinical Updates
    Cognition Therapeutics Reports 2025 Results, Clinical Updates

    26 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/26/3262885/0/en/Cognition-Therapeutics-Reports-Year-End-2025-Financial-Results-and-Provides-Clinical-Development-Update.html

    GLOBENEWSWIRE
    26 Mar 2026
    Share Share
    Cognition Therapeutics Shows Zervimesine's Effect On Dementia
    Cognition Therapeutics Shows Zervimesine's Effect On Dementia

    17 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/17/3257029/0/en/Cognition-Therapeutics-Presents-Evidence-of-Zervimesine-s-Impact-on-Neuropsychiatric-Symptoms-of-Dementia-with-Lewy-Bodies-at-AD-PD-2026.html

    GLOBENEWSWIRE
    17 Mar 2026
    Share Share
    Cognition Advances Zervimesine for Lewy Body Dementia Psychosis
    Cognition Advances Zervimesine for Lewy Body Dementia Psychosis

    02 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/02/3247262/0/en/Cognition-Therapeutics-Advancing-Zervimesine-CT1812-for-Dementia-with-Lewy-Bodies-DLB-Psychosis.html

    GLOBENEWSWIRE
    02 Mar 2026
    Share Share
    Cognition Therapeutics Extends Zervimesine Access Program
    Cognition Therapeutics Extends Zervimesine Access Program

    05 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/05/3232883/0/en/Cognition-Therapeutics-Extends-Expanded-Access-Program-for-Zervimesine-CT1812-in-Dementia-with-Lewy-Bodies.html

    GLOBENEWSWIRE
    05 Feb 2026
    Share Share
    Cognition Therapeutics Wraps FDA Type C Meeting For Zervimesine
    Cognition Therapeutics Wraps FDA Type C Meeting For Zervimesine

    27 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/27/3226367/0/en/Cognition-Therapeutics-Completes-Type-C-Meeting-with-FDA-for-Zervimesine-CT1812-in-Dementia-with-Lewy-Bodies.html

    GLOBENEWSWIRE
    27 Jan 2026
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.